BioCentury
ARTICLE | Company News

Esperion prices LDL-C candidate

March 2, 2018 5:22 PM UTC

Esperion Therapeutics Inc. (NASDAQ:ESPR) said it plans to price hypercholesterolemia candidate bempedoic acid (ETC-1002) at about $10 per day. The company said it is targeting patients who need less than 30% lowering in LDL-C and do not require treatment with a PCSK9 inhibitor.

Data from four Phase III trials of bempedoic acid as monotherapy and one Phase III trial in combination with Zetia ezetimibe to treat atherosclerotic cardiovascular disease (ASCVD) are expected this year. ...

BCIQ Company Profiles

Esperion Therapeutics Inc.

BCIQ Target Profiles

ATP citrate lyase (ACLY)